2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Ovarian Neoplasms in 56 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ovarian cancer has the highest mortality rate among gynecologic malignant tumors." | 5.46 | Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. ( Huang, CZ; Jiang, JH; Liu, YX; Ma, F; Peng, YM; Wang, QD; Wang, YF; Zhang, Y, 2017) |
| "Co-treatment of formononetin with pharmacological inhibitors (LY294002 or U0126) revealed additional anti-proliferative effects on the two human ovarian cancer cell types." | 1.48 | The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation. ( Bazer, FW; Lim, W; Park, S; Song, G, 2018) |
| "Delphinidin is a diphenylpropane-based polyphenolic ring structure-harboring compound, which exhibits a wide range of pharmacological activities, anti-tumor, anti-oxidant, anti-inflammatory, anti-angiogenic and anti-mutagenic activity." | 1.46 | Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells. ( Choi, KC; Kim, H; Kim, YJ; Ko, H; Lee, IH; Lee, KH; Lee, YK; Lim, WC; Park, SH; So, KA; Song, JH, 2017) |
| "Ovarian cancer has the highest mortality rate among gynecologic malignant tumors." | 1.46 | Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. ( Huang, CZ; Jiang, JH; Liu, YX; Ma, F; Peng, YM; Wang, QD; Wang, YF; Zhang, Y, 2017) |
| "Tumors of human ovarian cancer cell lines CP70 and A2780 were established by subcutaneous transplantation of cells in nude mice and the effect of metformin on MRP2 expression and tumor inhibition assessed." | 1.46 | Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. ( Du, J; Li, X; Ren, F; Shi, HR; Wang, JL; Wu, QH; Zhang, RT, 2017) |
| "Although ovarian cancer and breast cancer have comparable levels of HER2/ErbB2 expression, clinical studies of pertuzumab in epithelial ovarian cancer patients have not met the same level of success." | 1.42 | miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. ( Li, Y; Ma, C; Wang, J; Wuerkenbieke, D, 2015) |
| "In SKOV3 and IGROV1 human ovarian cancer cells, LY294002 and Akti-1/2 increased the percentage of cells in G(1) and reversed the cell cycle effects of cisplatin, paclitaxel, gemcitabine and topotecan." | 1.38 | Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. ( Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C, 2012) |
| "In high-grade ovarian cancer cultures, it has been shown that epidermal growth factor (EGF) induces cell invasion by activating an epithelial-mesenchymal transition (EMT)." | 1.38 | EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? ( Auersperg, N; Cheng, JC; Leung, PC, 2012) |
| "We treated 7 ovarian cancer cell lines with CDDP alone or with CDDP and either a PI3K inhibitor (LY294002), a MEK inhibitor (PD98059), or a MEK/ERK activator (phorbol 12-myristate 13-acetate [PMA]) and assessed cell viability, expression of MEK/ERK and PI3K/Akt, cell cycle distribution, and apoptosis." | 1.38 | Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. ( Harada, T; Itamochi, H; Kawaguchi, W; Kigawa, J; Kudoh, A; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K, 2012) |
| "SKOV3, OVCAR5 and IGROV1 human ovarian cancer cell lines were treated with cisplatin, LY294002 and a combination of both drugs." | 1.36 | Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. ( Dorigo, O; Eng, C; Fekete, M; Karam, AK; Santiskulvong, C; Zabih, S, 2010) |
| "The action of COX-2 on human ovarian cancer cell line (CAOV-3) and relative signal pathway has not been demonstrated." | 1.35 | Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. ( Cai, Y; Gong, H; Gu, P; Guo, S; Qi, J; Su, Y; Teng, L; Xu, Y, 2008) |
| "We treated two ovarian cancer cell lines ES-2 and SKOV3 with 17beta-estradiol, methoxyprogesterone acetate (MPA) only, or hormone combined with and Akt, MAPK pathway inhibitor, or transefected with siRNA targeting Akt sequenced with hormone." | 1.35 | Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. ( Cao, Q; Din, J; Feng, W; Feng, Y; Hua, K; Huang, Y; Yao, L; Zhang, Y; Zhao, Y, 2009) |
| " We hypothesized that targeted inhibition of specific signaling pathways in combination with conventional drugs may increase chemotherapeutic efficacy." | 1.35 | Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells. ( Chan, JL; Li, W; Lin, KT; Schlosshauer, PW; Wang, LH, 2009) |
| "Triptolide (TPL) has been identified as the active component of the Tripterygium wilfordii hook F plant and demonstrated to possess antitumor properties and induce apoptosis in a variety of tumor cell lines." | 1.35 | Role of triptolide as an adjunct chemotherapy for ovarian cancer. ( Nilsson, EE; Skinner, MK; Westfall, SD, 2008) |
| "OVCAR3 ovarian cancer cells express three sphingosine 1-phosphate (S1P) receptors, S1P(1), S1P(2), and S1P(3), but not S1P(4)." | 1.34 | S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells. ( Bae, YS; Kim, JM; Kim, MK; Kim, SD; Lee, HY; Lee, SY; Park, KS; Ryu, SH, 2007) |
| "Ascites are commonly found in ovarian cancer patients with advanced disease and are rich in cellular components and growth-promoting factors." | 1.34 | Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. ( Grondin, R; Lane, D; Piché, A; Rancourt, C; Robert, V, 2007) |
| "To study the inhibitory effect of tirapazamine (TPZ) combined with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), on the growth of human ovarian carcinoma cells." | 1.34 | [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells]. ( Ren, Y; Zha, X; Zhang, GN, 2007) |
| "with cells from the human ovarian cancer cell line, OVCAR-3." | 1.33 | Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. ( Hofmann, J; Hu, L; Jaffe, RB, 2005) |
| "Using human ovarian cancer cell line Caov3 cells, we observed that TSA induced cell death in a time- and dose-dependent manner and also inhibited cell migration." | 1.33 | Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. ( Di, W; Healey, S; Kouttab, N; Qiu, L; Sun, Y; Wan, Y; Wanebo, H; Yan, B; Zhou, C, 2006) |
| "Ovarian cancer is one of the most common cancers among women." | 1.32 | G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. ( Flynn, DC; Gao, N; Jiang, BH; Liu, KJ; Shi, X; Walker, V; Zhang, Z; Zhong, XS, 2004) |
| "In contrast, ovarian cancer cell lines OVCAR4 and OVCAR5, which have low basal levels of AKT activity, did not show increased cisplatin-induced apoptosis when pretreated with LY294002." | 1.32 | AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. ( Altomare, DA; De Rienzo, A; Godwin, AK; Klein-Szanto, AJ; Skele, KL; Testa, JR; Wang, HQ, 2004) |
| "Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha)." | 1.32 | Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. ( Hayasaka, T; Kawagoe, J; Kimura, A; Kurachi, H; Mabuchi, S; Motoyama, T; Murata, Y; Nishio, Y; Ohmichi, M; Ohta, T; Sakata, M; Seino-Noda, H; Takahashi, K; Tasaka, K; Testa, JR; Yada-Hashimoto, N, 2004) |
| "with the ovarian cancer cell line OVCAR-3." | 1.31 | In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). ( Gray, J; Hu, L; Jaffe, RB; Mills, GB; Zaloudek, C, 2000) |
| "inoculation with OVCAR-3 ovarian cancer cells, mice were treated i." | 1.31 | Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. ( Hofmann, J; Hu, L; Jaffe, RB; Lu, Y; Mills, GB, 2002) |
| "Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology." | 1.30 | PIK3CA is implicated as an oncogene in ovarian cancer. ( Baldocchi, R; Collins, C; Godfrey, T; Gray, JW; Kuo, WL; Lu, Y; Mills, GB; Pinkel, D; Powell, B; Shayesteh, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.57) | 18.2507 |
| 2000's | 30 (53.57) | 29.6817 |
| 2010's | 23 (41.07) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Selvendiran, K | 1 |
| Tong, L | 1 |
| Vishwanath, S | 1 |
| Bratasz, A | 1 |
| Trigg, NJ | 1 |
| Kutala, VK | 1 |
| Hideg, K | 1 |
| Kuppusamy, P | 1 |
| Lim, WC | 1 |
| Kim, H | 1 |
| Kim, YJ | 1 |
| Park, SH | 1 |
| Song, JH | 1 |
| Lee, KH | 1 |
| Lee, IH | 1 |
| Lee, YK | 1 |
| So, KA | 1 |
| Choi, KC | 2 |
| Ko, H | 1 |
| Yu, J | 1 |
| Hu, X | 1 |
| Chen, X | 2 |
| Zhou, Q | 1 |
| Jiang, Q | 1 |
| Shi, Z | 1 |
| Zhu, H | 1 |
| Huang, CZ | 1 |
| Wang, YF | 1 |
| Zhang, Y | 3 |
| Peng, YM | 1 |
| Liu, YX | 1 |
| Ma, F | 1 |
| Jiang, JH | 1 |
| Wang, QD | 1 |
| Du, J | 1 |
| Shi, HR | 1 |
| Ren, F | 1 |
| Wang, JL | 1 |
| Wu, QH | 1 |
| Li, X | 2 |
| Zhang, RT | 1 |
| Park, S | 1 |
| Bazer, FW | 1 |
| Lim, W | 1 |
| Song, G | 1 |
| Liu, Z | 1 |
| Zhang, S | 2 |
| Hou, F | 1 |
| Zhang, C | 1 |
| Gao, J | 1 |
| Wang, K | 1 |
| Xue, B | 1 |
| Wu, W | 1 |
| Huang, K | 1 |
| Xie, T | 1 |
| Xu, X | 1 |
| Zhang, H | 1 |
| Qi, C | 1 |
| Ge, J | 1 |
| Yu, Y | 1 |
| Badinloo, M | 1 |
| Esmaeili-Mahani, S | 1 |
| Rybalkina, EIu | 1 |
| Stromskaia, TP | 1 |
| Ovchinnikov, LP | 1 |
| Stavrovskaia, AA | 1 |
| Tan, N | 1 |
| Zheng, H | 1 |
| Huang, JJ | 1 |
| Yang, XR | 1 |
| Wu, XL | 1 |
| Zha, Y | 1 |
| Liu, Y | 1 |
| Luo, Z | 1 |
| Wuerkenbieke, D | 1 |
| Wang, J | 1 |
| Li, Y | 1 |
| Ma, C | 1 |
| Wang, D | 1 |
| Saga, Y | 1 |
| Sato, N | 1 |
| Nakamura, T | 1 |
| Takikawa, O | 1 |
| Mizukami, H | 1 |
| Matsubara, S | 1 |
| Fujiwara, H | 1 |
| Gu, P | 1 |
| Su, Y | 1 |
| Guo, S | 1 |
| Teng, L | 1 |
| Xu, Y | 1 |
| Qi, J | 1 |
| Gong, H | 1 |
| Cai, Y | 1 |
| Hua, K | 1 |
| Din, J | 1 |
| Cao, Q | 1 |
| Feng, W | 1 |
| Yao, L | 1 |
| Huang, Y | 1 |
| Zhao, Y | 1 |
| Feng, Y | 1 |
| Schlosshauer, PW | 1 |
| Li, W | 1 |
| Lin, KT | 1 |
| Chan, JL | 1 |
| Wang, LH | 1 |
| Liu, JJ | 1 |
| Lin, B | 2 |
| Hao, YY | 1 |
| Li, FF | 1 |
| Liu, DW | 1 |
| Qi, Y | 1 |
| Zhu, LC | 1 |
| Zhang, SL | 1 |
| Iwamori, M | 2 |
| Karam, AK | 1 |
| Santiskulvong, C | 2 |
| Fekete, M | 2 |
| Zabih, S | 1 |
| Eng, C | 2 |
| Dorigo, O | 2 |
| Peng, LP | 1 |
| Huang, JM | 1 |
| Zhang, GN | 2 |
| Zha, X | 2 |
| Ren, Y | 2 |
| Fan, Y | 1 |
| Deng, BF | 1 |
| Tomek, K | 1 |
| Wagner, R | 1 |
| Varga, F | 1 |
| Singer, CF | 1 |
| Karlic, H | 1 |
| Grunt, TW | 1 |
| Li, C | 1 |
| Liu, VW | 1 |
| Chan, DW | 1 |
| Yao, KM | 1 |
| Ngan, HY | 1 |
| Liu, D | 1 |
| Liu, J | 1 |
| Liu, S | 1 |
| Hou, R | 1 |
| Hao, Y | 1 |
| Liu, Q | 1 |
| Xu, CL | 1 |
| Lu, XL | 1 |
| Yan, XN | 1 |
| Wang, HL | 1 |
| Chen, SQ | 1 |
| Cheng, JC | 1 |
| Auersperg, N | 2 |
| Leung, PC | 2 |
| Nonaka, M | 1 |
| Itamochi, H | 1 |
| Kawaguchi, W | 1 |
| Kudoh, A | 1 |
| Sato, S | 2 |
| Uegaki, K | 1 |
| Naniwa, J | 1 |
| Shimada, M | 1 |
| Oishi, T | 1 |
| Terakawa, N | 1 |
| Kigawa, J | 1 |
| Harada, T | 1 |
| Xiao, L | 1 |
| He, C | 1 |
| Chen, Y | 1 |
| Zhou, JD | 1 |
| Zhang, L | 1 |
| Yang, N | 1 |
| Katsaros, D | 1 |
| Huang, W | 1 |
| Park, JW | 1 |
| Fracchioli, S | 1 |
| Vezzani, C | 1 |
| Rigault de la Longrais, IA | 1 |
| Yao, W | 1 |
| Rubin, SC | 1 |
| Coukos, G | 1 |
| Alfonso-De Matte, MY | 1 |
| Kruk, PA | 1 |
| Piccolo, E | 1 |
| Vignati, S | 1 |
| Maffucci, T | 1 |
| Innominato, PF | 1 |
| Riley, AM | 1 |
| Potter, BV | 1 |
| Pandolfi, PP | 1 |
| Broggini, M | 1 |
| Iacobelli, S | 1 |
| Innocenti, P | 1 |
| Falasca, M | 1 |
| Gao, N | 1 |
| Flynn, DC | 1 |
| Zhang, Z | 1 |
| Zhong, XS | 1 |
| Walker, V | 1 |
| Liu, KJ | 1 |
| Shi, X | 1 |
| Jiang, BH | 2 |
| Kimura, A | 2 |
| Ohmichi, M | 2 |
| Kawagoe, J | 2 |
| Kyo, S | 1 |
| Mabuchi, S | 2 |
| Takahashi, T | 1 |
| Ohshima, C | 1 |
| Arimoto-Ishida, E | 1 |
| Nishio, Y | 2 |
| Inoue, M | 1 |
| Kurachi, H | 2 |
| Tasaka, K | 2 |
| Murata, Y | 2 |
| Altomare, DA | 1 |
| Wang, HQ | 1 |
| Skele, KL | 1 |
| De Rienzo, A | 1 |
| Klein-Szanto, AJ | 1 |
| Godwin, AK | 1 |
| Testa, JR | 2 |
| Skinner, HD | 1 |
| Zheng, JZ | 1 |
| Fang, J | 1 |
| Agani, F | 1 |
| Hayasaka, T | 1 |
| Ohta, T | 1 |
| Takahashi, K | 1 |
| Yada-Hashimoto, N | 1 |
| Seino-Noda, H | 1 |
| Sakata, M | 1 |
| Motoyama, T | 1 |
| Westfall, SD | 2 |
| Skinner, MK | 2 |
| Parsons, R | 1 |
| Hu, L | 3 |
| Hofmann, J | 2 |
| Jaffe, RB | 3 |
| Coltella, N | 1 |
| Rasola, A | 1 |
| Nano, E | 1 |
| Bardella, C | 1 |
| Fassetta, M | 1 |
| Filigheddu, N | 1 |
| Graziani, A | 1 |
| Comoglio, PM | 1 |
| Di Renzo, MF | 1 |
| Noske, A | 1 |
| Kaszubiak, A | 1 |
| Weichert, W | 1 |
| Sers, C | 1 |
| Niesporek, S | 1 |
| Koch, I | 1 |
| Schaefer, B | 1 |
| Sehouli, J | 1 |
| Dietel, M | 1 |
| Lage, H | 1 |
| Denkert, C | 1 |
| Choi, JH | 1 |
| Zhou, C | 1 |
| Qiu, L | 1 |
| Sun, Y | 1 |
| Healey, S | 1 |
| Wanebo, H | 1 |
| Kouttab, N | 1 |
| Di, W | 1 |
| Yan, B | 1 |
| Wan, Y | 1 |
| Whitley, BR | 1 |
| Beaulieu, LM | 1 |
| Carter, JC | 1 |
| Church, FC | 1 |
| Park, KS | 1 |
| Kim, MK | 1 |
| Lee, HY | 1 |
| Kim, SD | 1 |
| Lee, SY | 1 |
| Kim, JM | 1 |
| Ryu, SH | 1 |
| Bae, YS | 1 |
| Lane, D | 1 |
| Robert, V | 1 |
| Grondin, R | 1 |
| Rancourt, C | 1 |
| Piché, A | 1 |
| Zhang, PN | 1 |
| Sun, H | 1 |
| Nilsson, EE | 1 |
| Shi, XY | 1 |
| Cai, XJ | 1 |
| Lei, JX | 1 |
| Cao, FJ | 1 |
| Pan, DF | 1 |
| Chen, P | 1 |
| Shayesteh, L | 1 |
| Lu, Y | 2 |
| Kuo, WL | 1 |
| Baldocchi, R | 1 |
| Godfrey, T | 1 |
| Collins, C | 1 |
| Pinkel, D | 1 |
| Powell, B | 1 |
| Mills, GB | 3 |
| Gray, JW | 1 |
| Friedrich, MJ | 1 |
| Zaloudek, C | 1 |
| Gray, J | 1 |
| Yuan, ZQ | 1 |
| Sun, M | 1 |
| Feldman, RI | 1 |
| Wang, G | 1 |
| Ma, X | 1 |
| Jiang, C | 1 |
| Coppola, D | 1 |
| Nicosia, SV | 1 |
| Cheng, JQ | 1 |
| Thant, AA | 1 |
| Nawa, A | 1 |
| Kikkawa, F | 1 |
| Ichigotani, Y | 1 |
| Sein, TT | 1 |
| Amin, AR | 1 |
| Hamaguchi, M | 1 |
56 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Ovarian Neoplasms
| Article | Year |
|---|---|
EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Caspase Inhibitors; Caspases; Cell | 2007 |
Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells.
Topics: Anthocyanins; Antineoplastic Agents; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Movem | 2017 |
CNOT7 modulates biological functions of ovarian cancer cells via AKT signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Exoribonucleases; Female; | 2021 |
Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ch | 2017 |
The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation.
Topics: Analysis of Variance; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Prolifera | 2018 |
Inhibition of Ca
Topics: Animals; Anoctamin-1; Cell Line, Tumor; Cell Proliferation; Chromones; Female; Gene Expression Regul | 2019 |
Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.
Topics: Antigens, Neoplasm; Benzylamines; Blotting, Western; Cell Line, Tumor; Cell Movement; Chemokine CXCL | 2013 |
Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; | 2014 |
[Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2013 |
[Effect of P13K/AKT signal pathway regulation on expression of XIAP and cIAP2 in ovarian cancer cells].
Topics: Adenocarcinoma; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Cell Proli | 2013 |
[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Blotting, Western; Caspase 3; Cell Cycle; Cell Lin | 2014 |
miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Ov | 2015 |
The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
Topics: Animals; Butadienes; Cell Line, Tumor; Chromones; Female; Hepatocyte Growth Factor; Heterografts; Hu | 2016 |
Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation.
Topics: Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Chromones; Cyclooxygenase 2; DNA Repl | 2008 |
Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway.
Topics: Cell Line, Tumor; Chromones; Estradiol; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; M | 2009 |
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Growth Processes; Cell | 2009 |
Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p27; ErbB Recepto | 2010 |
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromones; Cisplatin; Enzyme Act | 2010 |
[Influence of human epithelial ovarian cancer HO-8910 cells with modified survivin gene on the cell cycle distribution and chemosensitivity].
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Cisplatin; Drug | 2010 |
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Topics: 4-Butyrolactone; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Proteins; Cell Prolifer | 2011 |
LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Biomarkers, | 2012 |
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin | 2012 |
Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways.
Topics: Antibodies; Cell Line, Tumor; Chromones; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; C | 2012 |
[Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
Topics: Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Chromones; E | 2012 |
EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Chromones; Cystadenocarcinoma, Serous; Epidermal Growth | 2012 |
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chromones; Cisplatin; | 2012 |
[Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Cysteine-Rich Protein 61; | 2012 |
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Topics: Apoptosis; Catalytic Domain; Cell Division; Chromones; Endothelial Growth Factors; Enzyme Inhibitors | 2003 |
Phosphatidylinositol triphosphate kinase-dependent and c-jun NH2-terminal kinase-dependent induction of telomerase by calcium requires Pyk2.
Topics: Anisomycin; Calcium; Cell Line; Chromones; DNA-Binding Proteins; Edetic Acid; Enzyme Induction; Enzy | 2004 |
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Chromones; Cisplatin; Female; Fibronectins; Humans; Inositol Phosp | 2004 |
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Topics: Antibiotics, Antineoplastic; Blood Proteins; Cell Division; Chromones; Cyclin D1; Cyclin-Dependent K | 2004 |
Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines.
Topics: 14-3-3 Proteins; Cell Nucleus; Chromones; DNA-Binding Proteins; Enzyme Inhibitors; Estradiol; Estrog | 2004 |
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
Topics: Apoptosis; Cell Division; Chromones; Cisplatin; Enzyme Inhibitors; Female; Humans; Morpholines; Ovar | 2004 |
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.
Topics: Cell Line, Tumor; Chromones; DNA-Binding Proteins; Female; Humans; Hypoxia-Inducible Factor 1; Hypox | 2004 |
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Topics: Androstadienes; Animals; Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Agents, Phytog | 2004 |
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carboplatin; Cell Line, Tumor; Cell Pr | 2005 |
Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer.
Topics: Animals; Capillary Permeability; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Female; Humans; Mic | 2005 |
Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Topics: Animals; Ascites; Capillary Permeability; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Female; Hu | 2005 |
p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tu | 2006 |
Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; | 2007 |
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
Topics: Cell Line, Tumor; Chromones; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Enzyme Inhibit | 2006 |
Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Topics: Acetylation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromones; Dose-Res | 2006 |
Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Movement; Chromones; Female; Humans; Insulin; Insulin-Like Growth Factor I; M | 2007 |
S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells.
Topics: Blotting, Western; Calcium; Cell Line, Tumor; Cell Movement; Chemotaxis; Chromones; Enzyme Inhibitor | 2007 |
Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Ascitic Fluid; CASP8 and FADD-Like Apoptosis Regulating Protein; C | 2007 |
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cell Proliferation; Chromones; Cisplatin; Drug Synergism; | 2007 |
[Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Chromones; Dose-Response Relat | 2007 |
Role of triptolide as an adjunct chemotherapy for ovarian cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2008 |
[Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamil | 2008 |
PIK3CA is implicated as an oncogene in ovarian cancer.
Topics: Chromones; Chromosomes, Human, Pair 3; Enzyme Inhibitors; Female; Humans; In Situ Hybridization, Flu | 1999 |
Ovarian cancer investigators aim at cell signaling pathways.
Topics: Animals; Antineoplastic Agents; Calcium Channel Blockers; Cell Division; Chromones; Enzyme Inhibitor | 1999 |
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Topics: Animals; Apoptosis; Ascites; Cell Division; Chromones; Enzyme Inhibitors; Female; Humans; Mice; Mice | 2000 |
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adenosarcoma; Amino Acid Sequence; Apoptosis; B | 2000 |
Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.
Topics: Androstadienes; Butadienes; Chromones; Enzyme Inhibitors; Female; Fibronectins; Flavonoids; Humans; | 2000 |
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Chromones; Diseas | 2002 |